Ipca Labs, INE571A01038

Ipca Laboratories stock: Q2 profit rises as margins widen

Published on 11/18/2026 at 00:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ipca Laboratories stock drew attention after September-quarter net income and revenue rose year on year. EBITDA margin widened despite a legal provision.

Stronger quarterly performance

  • Ipca Laboratories reported a 32.5 percent year-on-year increase in September-quarter net income.
  • Revenue from operations rose 13.8 percent, while EBITDA margin expanded to 23 percent.
  • Unichem Laboratories recognised a GBP 1.9 million provision linked to a UK legal claim.
Ipca Labs, INE571A01038, Illustration mit AI erstellt.

Ipca Laboratories reported stronger second-quarter results for the period ended September 30, 2026, with consolidated net income rising 32.5 percent year on year to INR 375 crore. CNBC TV18 reported the figures on Thursday, November 5.

Revenue and margins advance

Revenue from operations increased 13.8 percent year on year to INR 2,910 crore from INR 2,557 crore. EBITDA rose 23.7 percent to INR 674 crore, lifting the EBITDA margin to 23 percent from 21 percent in the year-earlier quarter.

Domestic formulations income grew 14 percent to INR 1,157.20 crore. Export income advanced 17 percent to INR 951.39 crore, supporting the quarterly improvement across the business.

Legal provision affects subsidiary

Unichem Laboratories and its subsidiary Niche Generics recognised a GBP 1.9 million provision, equivalent to INR 24.26 crore, for a legal claim in the United Kingdom involving perindopril. The claim was brought by Laboratoires Servier and concerns contributions toward damages sought by UK health authorities.

The provision was recorded as an exceptional item in the consolidated results for the quarter and six months ended September 30, 2026. Niche Generics intends to pursue an early resolution, including a possible compromise.

Investor focus turns to execution

The results show stronger profitability alongside growth in domestic formulations and exports. Investors are likely to focus on whether the margin improvement can continue while the group addresses the legal matter at Unichem.

Ipca Laboratories at a glance

  • Company: Ipca Laboratories
  • ISIN: INE571A01038
  • Reporting period: Second quarter and six months ended September 30, 2026
  • Revenue from operations: INR 2,910 crore in the quarter
  • Net income: INR 375 crore in the quarter
  • EBITDA margin: 23 percent

The Indian pharmaceutical market remains the broader setting for Ipca Laboratories, alongside the TA-35 market environment.

Find more news and analyses on Ipca Laboratories stock.

Disclaimer...
en | INE571A01038 | IPCA LABS | boerse | 70528962 | bgmi